Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer's disease.

Brautigam H, Steele JW, Westaway D, Fraser PE, St George-Hyslop PH, Gandy S, Hof PR, Dickstein DL.

Mol Neurodegener. 2012 Nov 22;7:58. doi: 10.1186/1750-1326-7-58.


Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.

Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, Abramowski D, Kumar S, Yamaguchi H, Walter J, Fändrich M, Staufenbiel M, Thal DR.

Neurobiol Aging. 2012 Nov;33(11):2641-60. doi: 10.1016/j.neurobiolaging.2011.12.032. Epub 2012 Feb 2.


Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-β oligomers and no plaque pathology.

Price KA, Varghese M, Sowa A, Yuk F, Brautigam H, Ehrlich ME, Dickstein DL.

Mol Neurodegener. 2014 Oct 13;9:41. doi: 10.1186/1750-1326-9-41.


Hippocampal GABAergic neurons are susceptible to amyloid-β toxicity in vitro and are decreased in number in the Alzheimer's disease TgCRND8 mouse model.

Krantic S, Isorce N, Mechawar N, Davoli MA, Vignault E, Albuquerque M, Chabot JG, Moyse E, Chauvin JP, Aubert I, McLaurin J, Quirion R.

J Alzheimers Dis. 2012;29(2):293-308. doi: 10.3233/JAD-2011-110830.


Early fear memory defects are associated with altered synaptic plasticity and molecular architecture in the TgCRND8 Alzheimer's disease mouse model.

Steele JW, Brautigam H, Short JA, Sowa A, Shi M, Yadav A, Weaver CM, Westaway D, Fraser PE, St George-Hyslop PH, Gandy S, Hof PR, Dickstein DL.

J Comp Neurol. 2014 Jul 1;522(10):2319-35. doi: 10.1002/cne.23536.


Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T.

BMC Neurosci. 2010 Oct 14;11:130. doi: 10.1186/1471-2202-11-130.


Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway.

Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, Mufson EJ.

Exp Neurol. 2001 Aug;170(2):227-43.


Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis.

Verret L, Jankowsky JL, Xu GM, Borchelt DR, Rampon C.

J Neurosci. 2007 Jun 20;27(25):6771-80.


Intraneuronal APP and extracellular Aβ independently cause dendritic spine pathology in transgenic mouse models of Alzheimer's disease.

Zou C, Montagna E, Shi Y, Peters F, Blazquez-Llorca L, Shi S, Filser S, Dorostkar MM, Herms J.

Acta Neuropathol. 2015 Jun;129(6):909-20. doi: 10.1007/s00401-015-1421-4. Epub 2015 Apr 11.


Beta-amyloid, neuronal death and Alzheimer's disease.

Carter J, Lippa CF.

Curr Mol Med. 2001 Dec;1(6):733-7. Review.


Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease.

Saul A, Sprenger F, Bayer TA, Wirths O.

Neurobiol Aging. 2013 Nov;34(11):2564-73. doi: 10.1016/j.neurobiolaging.2013.05.003. Epub 2013 Jun 5.


Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease.

Schmitz C, Rutten BP, Pielen A, Schäfer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HW, Pradier L, Bayer TA.

Am J Pathol. 2004 Apr;164(4):1495-502.


Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.

Moon M, Hong HS, Nam DW, Baik SH, Song H, Kook SY, Kim YS, Lee J, Mook-Jung I.

J Alzheimers Dis. 2012;29(3):615-28. doi: 10.3233/JAD-2011-111778.


A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo.

Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H.

J Neurosci. 2010 Apr 7;30(14):4845-56. doi: 10.1523/JNEUROSCI.5825-09.2010.


Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease.

Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A.

Proc Natl Acad Sci U S A. 2012 May 29;109(22):8740-5. doi: 10.1073/pnas.1206171109. Epub 2012 May 16.


Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice.

O'Neil JN, Mouton PR, Tizabi Y, Ottinger MA, Lei DL, Ingram DK, Manaye KF.

J Chem Neuroanat. 2007 Nov;34(3-4):102-7. Epub 2007 May 31.


Early in vivo Effects of the Human Mutant Amyloid-β Protein Precursor (hAβPPSwInd) on the Mouse Olfactory Bulb.

Rusznák Z, Kim WS, Hsiao JH, Halliday GM, Paxinos G, Fu Y.

J Alzheimers Dis. 2016;49(2):443-57. doi: 10.3233/JAD-150368.


Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss.

Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T.

Am J Pathol. 2000 Jul;157(1):331-9. Erratum in: Am J Pathol 2000 Oct;157(4):1413.

Supplemental Content

Support Center